Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Dickson
Dr. Mark Dickson is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 14 years. He is one of 506 doctors at Memorial Sloan Kettering Cancer Center and one of 87 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2010 - 2027
CT State Medical License 2023 - 2025
NJ State Medical License 2020 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Start of enrollment: 2008 May 14
- Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Start of enrollment: 2010 Aug 01
- PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Start of enrollment: 2010 Sep 23
Publications & Presentations
PubMed
- Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022.Ayana E Morales, Gabrielle Benson, Stephanie Glavan, Rosemary Giuliano, Mark A Dickson
The Oncologist. 2025-03-10 - Harmonization of the Upfront Osteosarcoma Treatment Paradigm for Adolescents and Young Adults.Nicole P Daukshus, Viswatej Avutu, Emily Long Sarro, Michael D Kinnaman, Emily K Slotkin
Journal of Adolescent and Young Adult Oncology. 2025-02-01 - Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, Angela M DeMichele, Richard Piekarz
Clinical Cancer Research. 2025-01-06
Journal Articles
- TP53 Mutations Emerge with HDM2 Inhibitor SAR405838 Treatment in De-Differentiated LiposarcomaMark A Dickson, Edwin Choy, Nature
Press Mentions
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
Big, Fat Tumors: Liposarcomas Can Top 70 PoundsOctober 5th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
